Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Clinical trial NCT06711471 · RECRUITING
Trial details
- NCT number
- NCT06711471
- Sponsor
- LIN YANG
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-14
- Primary completion
- 2026-11-13
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.